Single Ventricle Heart Disease Market Size

Single Ventricle Heart Disease Market

DELHI, DELHI, INDIA, June 21, 2024 /EINPresswire.com/ -- DelveInsight’s comprehensive report titled “Single Ventricle Heart Disease Market Insights, Epidemiology, and Market Forecast – 2034” offers a detailed analysis of single ventricle heart disease. The report presents historical and projected epidemiological data covering Total Incident Cases of Single Ventricle Heart Disease further segmented by Type and Gender. In addition to epidemiology, the market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2020 to 2034.

Explore the intricate details of the Single Ventricle Heart Disease Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Single Ventricle Heart Disease Market Forecast. Click here to stay ahead in healthcare innovation @ Single Ventricle Heart Disease Market Size

Key Takeaways from the Single Ventricle Heart Disease Market Report
• In June 2024:- Mezzion Pharma Co. Ltd- This study will evaluate the clinical efficacy and safety of udenafil, an orally administered, potent and selective inhibitor of PDE5, versus placebo for the treatment of adolescent who have had the Fontan procedure. This study is a 26 week, prospective, multicenter, randomized, double-blinded, placebo-controlled safety and efficacy study of udenafil vs. placebo in adolescent subjects who have had the Fontan procedure.
• In June May 2024:- Merck Sharp & Dohme LLC- A Phase 3, Single-arm, Open-label Extension of the Vericiguat VALOR Study in Pediatric Participants With Heart Failure Due to Systemic Left Ventricular Systolic Dysfunction (VALOR EXT). The primary objective of this study is to monitor the safety and tolerability of vericiguat.
• As per Heaton & Heller (2022), hypoplastic left heart syndrome, the most common form of univentricular heart disease, is seen in 2 to 3 per 10,000 births with a higher incidence in males.
• Hypoplastic left heart syndrome is almost universally fatal if untreated but improves to 60% to 70% survival with partial revisions.
• The leading Single Ventricle Heart Disease Companies such as Mezzion, Gene Techno Science, Longeveron, and others.
• Promising Single Ventricle Heart Disease Therapies such as Udenafil, REGN5381. Vericiguat tablet, Riociguat, and others.

Navigate the complexities of the Tend Single Ventricle Heart Disease Market: Gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Single Ventricle Heart Disease Market Forecast. Click here to get more insights @ Single Ventricle Heart Disease Treatment Market

Single Ventricle Heart Disease Epidemiology Segmentation in the 7MM
• Total Single Ventricle Heart Disease Incident Cases
• Single Ventricle Heart Disease Gender-specific Cases
• Single Ventricle Heart Disease Type-specific Cases
• Single Ventricle Heart Disease Treatable Cases

Delve deep into the Single Ventricle Heart Disease Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Single Ventricle Heart Disease Market Forecast. Click here to shape the future @ Single Ventricle Heart Disease Prevalence

Single Ventricle Heart Disease Market Insights
Various types of single ventricle heart defects are very different, and treatment for each must be customized. Many patients with single ventricle defects may also require a cardiac catheterization during childhood. Even though the types of defects are different, the general treatment approach for single ventricle heart defects is similar. Single ventricle defects require a series of open-heart procedures, performed over several years. This is called “staged reconstruction” and includes three surgeries: The Norwood procedure, The hemi-Fontan or Glenn operation, The Fontan procedure. During this series of operations, surgeons reconfigure the heart and circulatory system.

Single Ventricle Heart Disease Therapeutics Market
The burden of Single Ventricle Heart Disease is objectively significant, there is a shocking lack of data available on long-term outcomes and economic impact, with no comprehensive resource that describes the full spectrum. Therefore, efforts to describe the effects of this disease rely heavily upon data compiled on generalized CHDs to describe the effects of this disease, which fail to account for the specificity and extent of impacts unique to Single Ventricle Heart Disease.

Unlock insights into the Single Ventricle Heart Disease Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Single Ventricle Heart Disease Market Forecast. Click here @ Single Ventricle Heart Disease Market Drivers and Barriers- https://www.delveinsight.com/sample-request/single-ventricle-heart-disease-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=ypr

Single Ventricle Heart Disease Market Dynamics
The Single Ventricle Heart Disease market dynamics are anticipated to change in the coming years owing to the increasing R&D activities, and expected launch of emerging therapies during the forecasted period 2023–2034. The approval of the emerging treatments will be a milestone for patients who have been suffering from single ventricle heart disease.

Single Ventricle Heart Disease Drugs Uptake
• Udenafil: Mezzion Pharma Co. Ltd
Udenafil is a long acting highly selective phosphodiesterase-5 inhibitor that is orally administered. Inhibition of PDE5 results in the relaxation of pulmonary vascular smooth muscle cells and vasodilation of the pulmonary vascular bed. In 2021, Mezzion announced positive data from a Phase III efficacy and safety trial (FUEL Trial) and its open label extension trial (FUEL OLE Trial) that concerns the treatment of a very large subgroup of patients with congenital single ventricle heart disease (SVHD) who have Fontan physiology was presented to the FDA in a Type C meeting.

• JRM-001: Metcela Inc.
JRM is developing a new cell therapy product JRM-001 for serious cardiac diseases, namely pediatric congenital heart disease, using cardiac stem cells (CSCs). JRM-001 is targeting single ventricle, which is one of the most common pediatric congenital heart diseases affecting about 400-500 patients annually. Currently JRM-001 is going through Phase III APOLLON clinical trial in Japan to evaluate the improvement of cardiac function after standard surgical repair of the heart.

Gain a strategic edge in the Single Ventricle Heart Disease Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Single Ventricle Heart Disease Market Forecast. Click here to lead in advancements @ Single Ventricle Heart Disease Clinical Trials Assessment- https://www.delveinsight.com/sample-request/single-ventricle-heart-disease-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Single Ventricle Heart Disease Market Report
• Coverage- 7MM
• Single Ventricle Heart Disease Companies- Mezzion, Gene Techno Science, Longeveron, and others.
• Single Ventricle Heart Disease Therapies- Udenafil, REGN5381. Vericiguat tablet, Riociguat, and others.
• Single Ventricle Heart Disease Market Dynamics: Single Ventricle Heart Disease Market drivers and Single Ventricle Heart Disease Market Barriers
• Single Ventricle Heart Disease Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Single Ventricle Heart Disease Unmet Needs, KOL's views, Analyst's views, Single Ventricle Heart Disease Market Access and Reimbursement

Discover the latest advancements in Single Ventricle Heart Disease Treatment by visiting our website. Stay informed about how we're transforming the future @ https://www.delveinsight.com/sample-request/single-ventricle-heart-disease-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Executive Summary of Single Ventricle Heart Disease
3. Competitive Intelligence Analysis for Single Ventricle Heart Disease
4. Single Ventricle Heart Disease: Market Overview at a Glance
5. Single Ventricle Heart Disease: Disease Background and Overview
6. Patient Journey
7. Single Ventricle Heart Disease Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Single Ventricle Heart Disease Unmet Needs
10. Key Endpoints of Single Ventricle Heart Disease Treatment
11. Single Ventricle Heart Disease Marketed Products
12. Single Ventricle Heart Disease Emerging Therapies
13. Single Ventricle Heart Disease: Seven Major Market Analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Single Ventricle Heart Disease
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Yash Bhardwaj
DelveInsight
+91 9650213330
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.